Baltimore, MD, October 31, 2024 – Sysmex Inostics, a subsidiary of Japan’s Sysmex Corporation and a Baltimore-based biotechnology firm with a CLIA-certified laboratory, is proud to announce its participation at the AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation, taking place on November 13-16, 2024 (San Diego, CA). Sysmex Inostics will be presenting two groundbreaking posters emphasizing clinical utility of HPV-SEQ, our commercially available next-generation sequencing (NGS) assay performed in a CLIA validated lab. The HPV-SEQ assay detects cell-free HPV DNA, enabling monitoring of treatment response and surveillance in HPV-related oropharyngeal cancer.
Sysmex Inostics’ presence at the AACR Liquid Biopsy Conference underscores the company’s commitment in advancing precision oncology for cancer research and clinical practice for oropharyngeal and other HPV-associated cancers. Sysmex Inostics has been a leader in liquid biopsy since 2008, with a diverse range of ultra-sensitive, CLIA-validated liquid biopsy assays in nearly all cancer types. With robust experience in NGS-based molecular diagnostics, Sysmex Inostics is currently pioneering the development of HPV-SEQ for HPV-associated cancers. “Participating in the AACR Liquid Biopsy Conference is an exciting opportunity for Sysmex Inostics to share latest developments using our ultrasensitive HPV-SEQ assay with the scientific and clinical communities,” said Anna Starus, Associate Director, Medical Affairs and Product Development of Sysmex Inostics. “We are thrilled to demonstrate how our HPV-SEQ assay can improve detection, treatment monitoring, and surveillance of HPV-associated oropharyngeal cancer and offer actionable insights for optimizing treatment decisions.”
Poster presentations
Analytical and clinical validation of HPV-SEQ, an NGS-based liquid biopsy platform for detection and quantification of human papillomavirus circulating tumor DNA (Poster #A019)
Presented by: Samaneh Eickelschulte, Ph.D., Sysmex Inostics GmbH, Hamburg, Germany
Session: Poster Session A
Session Date and Time: Thursday, November 14, 5:15 p.m.-7:15 p.m.
Cell-free HPV-DNA dynamics during induction chemotherapy and response-stratified de-escalation in viral-mediated oropharyngeal cancer (Poster #B023)
Presented by: Ari Rosenberg, MD, University of Chicago, Chicago, Illinois
Session: Poster Session B
Session Date and Time: Friday, November 15, 6:15 p.m.-8:15 p.m.
For more information on Sysmex Inostics and HPV-SEQ, please visit our table at the Grand Ballroom Foyer, Omni San Diego Hotel.
About HPV-SEQ
HPV-SEQ is an ultra-sensitive, NGS-based assay for detection and quantification of cell-free HPV-DNA. It can detect as low as 2 copies of HPV 16 and HPV 18 DNA, offering high analytical and clinical sensitivity. It is currently being utilized in several clinical trials of HPV-associated cancers for treatment response monitoring and surveillance.
About Sysmex Inostics
Sysmex Inostics, Inc., a subsidiary of Japan’s Sysmex Corporation, is a Baltimore-based biotechnology firm and CLIA-certified lab offering biomarker testing to accelerate the development of personalized medicine.
Pioneering liquid biopsy technology with OncoBEAM™ in 2008, Sysmex Inostics now provides next generation sequencing Plasma-Safe-SeqS technology panels. The Plasma-Safe-SeqS panels empower more accurate detection of low-frequency biomarkers with ultra-sensitive 0.03% to 0.05% allele frequency from a simple blood draw to expedite studies and uncover deeper insights into therapy response. The company offers CLIA validated NGS testing services for HPV16/18 quantification, HNSCC, AML, breast cancer, and solid tumors impacted by RAS-RAF and PI3K signaling pathways.
For more information, refer to www.sysmex-inostics.com or email info@sysmex-inostics.com